Arrowhead Pharmaceuticals (ARWR) Other financing activities (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 10 years of Other financing activities data on file, last reported at $10.1 million in Q1 2026.

• Quarterly Other financing activities rose 146.65% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.9 million (up 880.42% YoY) and the FY2025 annual result came in at $25.0 million, changed N/A from the prior year.
• Other financing activities fell to $10.1 million in Q1 2026, from $21.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $249.4 million in Q1 2023 to a low of -$247.8 million in Q2 2023.
• A 5-year average of $3.5 million and a median of $2.2 million in 2022 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 6585.18% in 2023, down 6540.79% in 2023.
• Tracing ARWR's Other financing activities over 5 years: stood at $576000.0 in 2022, then slumped by 487.5% to -$2.2 million in 2023, then soared by 1220.07% to $25.0 million in 2024, then slipped by 13.01% to $21.7 million in 2025, then tumbled by 53.35% to $10.1 million in 2026.
• The last three Other financing activities figures came in at $10.1 million (Q1 2026), $21.7 million (Q2 2025), and -$21.7 million (Q1 2025), per Business Quant data.